Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daiichi Sankyo Co., Ltd. (4568:JPX), powered by AI.
Daiichi Sankyo Co., Ltd. is currently trading at ¥2,546. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Daiichi Sankyo Co., Ltd. on Alpha Lenz.
Daiichi Sankyo Co., Ltd.'s P/E ratio is 16.3.
“Daiichi Sankyo Co., Ltd. trades at a P/E of 16.3 (fair value) with strong ROE of 17.9%. 3Y revenue CAGR of 21.8% highlights clear growth momentum.”
Ask for details →Daiichi Sankyo Co., Ltd. is a prominent pharmaceutical company based in Japan, specializing in the research, development, and manufacturing of pharmaceutical products. The company's primary focus is on developing innovative treatments across several critical therapeutic areas such as oncology, cardiovascular diseases, and rare genetic conditions. Notable for its robust pipeline of drugs, Daiichi Sankyo aims to leverage cutting-edge science in antibody-drug conjugates and other novel drug delivery systems to provide advanced treatments for unmet medical needs. As a key player in the global pharmaceutical industry, Daiichi Sankyo impacts multiple sectors, including healthcare services and biotechnology. Its strategic collaborations with other leading global pharmaceutical companies further enhance its growth prospects and innovation capabilities. Headquartered in Tokyo, Japan, and with a broad international footprint, Daiichi Sankyo holds significant market significance. It plays a vital role in advancing global healthcare solutions, ensuring a pipeline of emerging therapies can address future challenges in medical treatment.
“Daiichi Sankyo Co., Ltd. trades at a P/E of 16.3 (fair value) with strong ROE of 17.9%. 3Y revenue CAGR of 21.8% highlights clear growth momentum.”
Ask for details →Daiichi Sankyo Co., Ltd. (ticker: 4568) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 19,765 employees. Market cap is $4.8T.
The current price is 2,546 with a P/E ratio of 16.32x and P/B of 2.97x.
ROE is 17.86% and operating margin is 17.60%. Annual revenue is $1.9T.